CY1121591T1 - Ογκολυτικος ιος απλου ερπητα και θεραπευτικες χρησεις αυτου - Google Patents

Ογκολυτικος ιος απλου ερπητα και θεραπευτικες χρησεις αυτου

Info

Publication number
CY1121591T1
CY1121591T1 CY20191100111T CY191100111T CY1121591T1 CY 1121591 T1 CY1121591 T1 CY 1121591T1 CY 20191100111 T CY20191100111 T CY 20191100111T CY 191100111 T CY191100111 T CY 191100111T CY 1121591 T1 CY1121591 T1 CY 1121591T1
Authority
CY
Cyprus
Prior art keywords
hsv
herpes simplex
variants
therapeutic uses
oncolytic virus
Prior art date
Application number
CY20191100111T
Other languages
English (en)
Inventor
Ian J. Mohr
Matthew C. Mulvey
Original Assignee
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University filed Critical New York University
Publication of CY1121591T1 publication Critical patent/CY1121591T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με παραλλαγές ιού απλού έρπητα (HSV) που επιλεκτικά μολύνουν και αντιγράφονται σε καρκινικά κύτταρα, συμπεριλαμβανομένων στελεχών HSV που επιλεκτικά μολύνουν και αντιγράφονται σε κύτταρα καρκίνου της ουροδόχου κύστης. Κατά προτίμηση οι HSV της εφεύρεσης έχουν άθικτα ενδογενή γονίδια Us11 και Us12 και τα γονίδια τους που κωδικοποιούν ICP34.5 έχουν αντικατασταθεί με ένα γονίδιο που κωδικοποιεί Us11 συγχωνευμένο με έναν άμεσο πρώιμο (ΙΕ) προωθητή HSV. Οι παραλλαγές HSV της εφεύρεσης περιλαμβάνουν επίσης ένα ή περισσότερα επιπρόσθετα ετερόλογα γονίδια που κωδικοποιούν ανοσορυθμιστικά πολυππεπτίδια. Παρέχονται επίσης μέθοδοι και συνθέσεις για τη χρήση αυτών των παραλλαγών HSV, π.χ. για την αγωγή καρκίνου σε ένα υποκείμενο.
CY20191100111T 2011-09-08 2019-01-24 Ογκολυτικος ιος απλου ερπητα και θεραπευτικες χρησεις αυτου CY1121591T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161532335P 2011-09-08 2011-09-08
PCT/US2012/054206 WO2013036795A2 (en) 2011-09-08 2012-09-07 Oncolytic herpes simplex virus and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
CY1121591T1 true CY1121591T1 (el) 2020-07-31

Family

ID=47832785

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100111T CY1121591T1 (el) 2011-09-08 2019-01-24 Ογκολυτικος ιος απλου ερπητα και θεραπευτικες χρησεις αυτου

Country Status (14)

Country Link
US (5) US9623059B2 (el)
EP (1) EP2753355B1 (el)
CA (1) CA2846372C (el)
CY (1) CY1121591T1 (el)
DK (1) DK2753355T3 (el)
ES (1) ES2704632T3 (el)
HR (1) HRP20182194T1 (el)
HU (1) HUE041799T2 (el)
LT (1) LT2753355T (el)
PL (1) PL2753355T3 (el)
PT (1) PT2753355T (el)
RS (1) RS58146B1 (el)
SI (1) SI2753355T1 (el)
WO (1) WO2013036795A2 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA39818A (fr) * 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
EP3268034A4 (en) * 2015-03-05 2018-11-14 Northwestern University Non-neuroinvasive viruses and uses thereof
EP3400291B2 (en) * 2016-01-08 2024-02-28 Replimune Limited Engineered virus
EP3478321A4 (en) * 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
MA51630A (fr) 2017-03-15 2020-01-22 Amgen Inc Utilisation de virus oncolytiques, seuls ou en combinaison avec un inhibiteur de point de contrôle immunitaire, pour le traitement du cancer
JP2020519666A (ja) 2017-05-15 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定性のウイルス含有組成物
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
HUE058233T2 (hu) 2017-08-03 2022-07-28 Amgen Inc Interleukin-21-muteinek és kezelési eljárások
US10640504B2 (en) 2017-09-08 2020-05-05 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
WO2019075233A1 (en) * 2017-10-12 2019-04-18 Massachusetts Eye And Ear Infirmary METHODS FOR RAPID DETECTION AND IDENTIFICATION OF PATHOGENIC OLEITY AGENTS
JP2021508477A (ja) 2017-12-29 2021-03-11 オンコラス， インコーポレイテッド 治療用ポリペプチドの腫瘍溶解性ウイルス送達
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
US11390650B2 (en) 2018-02-05 2022-07-19 The Brigham And Women's Hospital, Inc. Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
EP3902529A1 (en) 2018-12-27 2021-11-03 Amgen Inc. Lyophilized virus formulations
BR112021017551A2 (pt) 2019-03-05 2021-11-09 Amgen Inc Uso de vírus oncolíticos para o tratamento de câncer
WO2020181058A1 (en) 2019-03-05 2020-09-10 Massachusetts Institute Of Technology Dna launched rna replicon system (drep) and uses thereof
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
CN111850126B (zh) * 2020-08-06 2022-11-01 北京市神经外科研究所 溶瘤病毒在葡萄膜黑色素瘤治疗上的应用、治疗效果的标记物及其检测试剂
JP2024517232A (ja) 2021-05-05 2024-04-19 ヤンセン バイオテツク，インコーポレーテツド 腫瘍溶解性ｈｓｖの普遍的再標的化
WO2024073416A2 (en) * 2022-09-26 2024-04-04 The General Hospital Corporation Modified oncolytic herpes simplex virus (ohsv) and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818694A (en) 1982-07-20 1989-04-04 American Cyanamid Company Production of herpes simplex viral protein
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2601676B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Procede de preparation du taxol et du desacetyl-10 taxol
FR2629818B1 (fr) 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
US5071743A (en) 1989-10-27 1991-12-10 Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada Process for conducting site-directed mutagenesis
FR2662441B1 (fr) 1990-05-22 1992-10-23 Rhone Poulenc Sante Procede de preparation enantioselective de derives de la phenylisoserine.
FR2662440B1 (fr) 1990-05-22 1992-07-31 Rhone Poulenc Sante Procede de preparation stereoselective de derives de la phenylisoserine.
EP0592597B1 (en) 1991-07-01 2001-09-26 Berlex Laboratories, Inc. Novel mutagenesis methods and compositions
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
EP0906420A1 (en) 1996-06-07 1999-04-07 Massachusetts Institute Of Technology Programmed sequential mutagenesis
US5780270A (en) 1996-07-17 1998-07-14 Promega Corporation Site-specific mutagenesis and mutant selection utilizing antibiotic-resistant markers encoding gene products having altered substrate specificity
US6379674B1 (en) * 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
AU6120600A (en) * 1999-06-08 2000-12-28 Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
IL131212A0 (en) * 1999-08-03 2001-01-28 Yissum Res Dev Co Recombinant virus and live-virus vaccines
WO2001053506A2 (en) * 2000-01-21 2001-07-26 Biovex Limited Virus strains for the oncolytic treatment of cancer
US6682892B2 (en) 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
EP1381280B1 (en) * 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
US7731952B2 (en) * 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
EP2089513A1 (en) * 2006-12-07 2009-08-19 Publiekrechtelijke rechtspersoon Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum Use of a varicellovirus tap-inhibitor for the induction of tumor- or virus-specific immunity against teipp

Also Published As

Publication number Publication date
RS58146B1 (sr) 2019-02-28
DK2753355T3 (en) 2019-01-28
US20200113956A1 (en) 2020-04-16
HUE041799T2 (hu) 2019-05-28
US20220031779A1 (en) 2022-02-03
PT2753355T (pt) 2019-02-01
US10105404B2 (en) 2018-10-23
EP2753355A2 (en) 2014-07-16
US11147846B2 (en) 2021-10-19
WO2013036795A2 (en) 2013-03-14
US9623059B2 (en) 2017-04-18
EP2753355A4 (en) 2015-05-06
US20180369301A1 (en) 2018-12-27
CA2846372A1 (en) 2013-03-14
LT2753355T (lt) 2019-01-25
ES2704632T3 (es) 2019-03-19
US20150110822A1 (en) 2015-04-23
US20170216381A1 (en) 2017-08-03
HRP20182194T1 (hr) 2019-02-22
US10456432B2 (en) 2019-10-29
EP2753355B1 (en) 2018-10-24
WO2013036795A3 (en) 2014-05-15
SI2753355T1 (sl) 2019-02-28
CA2846372C (en) 2021-01-12
PL2753355T3 (pl) 2019-04-30

Similar Documents

Publication Publication Date Title
CY1121591T1 (el) Ογκολυτικος ιος απλου ερπητα και θεραπευτικες χρησεις αυτου
GB2573664A (en) Viral methods of T cell therapy
MX2021001158A (es) Vector hsv oncolitico.
CY1122654T1 (el) Ενωσεις για βελτιωμενη iiκη μεταγωγη
CO2019006541A2 (es) Administración viral de neoantígenos
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
CY1124437T1 (el) Ανθρωπινα αντισωματα κατα toy pd-l1
CY1124015T1 (el) Ανασυνδυασμενα ανυσματα hcmv και rhcmv εγκωδiκευοντας ενα ετερολογο αντιγονο που απομονωνεται απο ιο ηπατιτιδας β και χρησεις εξ αυτων
CY1119893T1 (el) Προϊοντα συζευξης cc-1065 αναλογων και διλειτουργικων συνδετων
EP4219696A3 (en) Oncolytic virus strain
CY1118562T1 (el) Ποντικοι οι οποιοι δημιουργουν πρωτεϊνες δεσμευσης οι οποιες περιλαμβανουν επικρατειες vl
CY1122800T1 (el) Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων
CY1122123T1 (el) Συνθεσεις λιπιδικου νανοσωματιδιου και μεθοδοι για απελευθερωση mrna
CY1122107T1 (el) Τροποποιημενες πρωτεϊνες δεσμευσης οι οποιες αναστελλουν την αλληλεπιδραση υποδοχεα vegf-a
CY1126149T1 (el) Ανασυνδυασμενα ιικα σωματιδια με τροποποιημενο τροπισμο και χρησεις αυτων για τη στοχευμενη εισαγωγη γενετικου υλικου σε ανθρωπινα κυτταρα
CY1125338T1 (el) Λιποκατιονικα δενδριμερη και χρησεις εξ αυτων
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EP3380621A4 (en) CONSTRUCTION OF THE VECTOR OF OBLIGATES ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CANCER THERAPY CONSTRUCTIONS
CY1121993T1 (el) Συνθεσεις που χαρακτηριζονται απο εναν εξασθενημενο ιο ψευδοπανωλης και μεθοδοι χρησης για την αντιμετωπιση της νέοπλασιας
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
CY1122850T1 (el) Υπερδιακλαδισμενος πολυ (βητα-αμινοεστερας) για γονιδιακη θεραπεια
WO2011130749A3 (en) Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors
MX2018011306A (es) Vector multimodal para infeccion de celulas dentriticas.
CY1122004T1 (el) Γενετικα τροποποιημενα μεσεγχυματικα βλαστικα κυτταρα που εκφραζουν την αλφα-1 αντιθρυψινη (αττ)
AU2018273963A1 (en) Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells